David Schultz
Research Subjects
David Schultz has a total of 537 co-authors. Here are the top co-authors by number of shared publications:
- Christopher R. Levi
Hunter New England Local Health District, New Lambton Heights, New South Wales, 2305, Australia
5 shared publications - Geoffrey Alan Donnan
Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Victoria, Australia (G.A.D.).
4 shared publications - Mary-Louise Rogers
Flinders Health and Medical Research Institute College of Medicine and Public Health Flinders University Adelaide 5042 SA Australia
4 shared publications - Aashray K. Gupta
University of Adelaide, Adelaide, Australia; Gold Coast University Hospital, Southport, Australia
3 shared publications Andre Peeters
3 shared publicationsLeonid Churilov
Department of Medicine and Neurology, Melbourne Brain Centre, University of Melbourne, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
3 shared publications
Latest Publications
- Open Access
- 24 October 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (6) , fcad287
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Amyotrophic lateral sclerosis is a relentless neurodegenerative disease that is mostly fatal within 3–5 years and is diagnosed on evidence of progressive upper and lower motor neuron degeneration. Around 15% of those with amyotrophic lateral sclerosis also have frontotemporal degeneration, and gene mutations account for ∼10%. Amyotrophic lateral sclerosis is a variable heterogeneous disease, and it is becoming increasingly clear that numerous different disease processes culminate in the final degeneration of motor neurons. There is a profound need to clearly articulate and measure pathological process that occurs. Such information is needed to tailor treatments to individuals with amyotrophic lateral sclerosis according to an individual’s pathological fingerprint. For new candidate therapies, there is also a need for methods to select patients according to expected treatment outcomes and measure the success, or not, of treatments. Biomarkers are essential tools to fulfil these needs, and urine is a rich source for candidate biofluid biomarkers. This review will describe promising candidate urinary biomarkers of amyotrophic lateral sclerosis and other possible urinary candidates in future areas of investigation as well as the limitations of urinary biomarkers.
- 24 October 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (6) , fcad287
Open AccessUrinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Amyotrophic lateral sclerosis is a relentless neurodegenerative disease that is mostly fatal within 3–5 years and is diagnosed on evidence of progressive upper and lower motor neuron degeneration. Around 15% of those with amyotrophic lateral sclerosis also have frontotemporal degeneration, and gene mutations account for ∼10%. Amyotrophic lateral sclerosis is a variable heterogeneous disease, and it is becoming increasingly clear that numerous different disease processes culminate in the final degeneration of motor neurons. There is a profound need to clearly articulate and measure pathological process that occurs. Such information is needed to tailor treatments to individuals with amyotrophic lateral sclerosis according to an individual’s pathological fingerprint. For new candidate therapies, there is also a need for methods to select patients according to expected treatment outcomes and measure the success, or not, of treatments. Biomarkers are essential tools to fulfil these needs, and urine is a rich source for candidate biofluid biomarkers. This review will describe promising candidate urinary biomarkers of amyotrophic lateral sclerosis and other possible urinary candidates in future areas of investigation as well as the limitations of urinary biomarkers.
- 31 May 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 113, 130-141
Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review
- 31 May 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 113, 130-141
Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review
- Open Access
- 23 April 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 112, 58-63
Single count breath test for the evaluation of respiratory function in Myasthenia Gravis: A systematic review
- 23 April 2023
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 112, 58-63
Open AccessSingle count breath test for the evaluation of respiratory function in Myasthenia Gravis: A systematic review
- 22 December 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (3) , 10-11
Factors associated with delay to carotid endarterectomy for acute ischaemic stroke in South Australia: A multicentre retrospective cohort study
- 22 December 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (3) , 10-11
Factors associated with delay to carotid endarterectomy for acute ischaemic stroke in South Australia: A multicentre retrospective cohort study
- 11 January 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (4) , 990-999
Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis
Background and purpose: The aim was to evaluate urinary neopterin, a marker of pro‐inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75ECD).Methods: This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75ECD were measured using enzyme‐linked immunoassays. Baseline and longitudinal changes in clinical measures, neopterin and urinary p75ECD were examined, and prognostic utility was explored by survival analysis.Results: At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = −0.36, p = 0.01). Combining previously published urinary p75ECD results from 22 ALS patients with a further 24 ALS patients, baseline urinary p75ECD was also higher compared to healthy controls (6.0 ± 2.7 vs. 3.2 ± 1.0 ng/mg creatinine, p < 0.0001) and correlated with the Revised ALS Functional Rating Scale (r = −0.36, p = 0.01). Urinary neopterin and p75ECD correlated with each other at baseline (r = 0.38, p = 0.009). In longitudinal analysis, urinary neopterin increased on average (±SE) by 6.8 ± 1.1 µmol/mol creatinine per month (p < 0.0001) and p75ECD by 0.19 ± 0.02 ng/mg creatinine per month (p < 0.0001) from diagnosis in 29 ALS patients.Conclusion: Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti‐inflammatory therapies.
- 11 January 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (4) , 990-999
Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis
Background and purpose: The aim was to evaluate urinary neopterin, a marker of pro‐inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75ECD).Methods: This was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75ECD were measured using enzyme‐linked immunoassays. Baseline and longitudinal changes in clinical measures, neopterin and urinary p75ECD were examined, and prognostic utility was explored by survival analysis.Results: At baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = −0.36, p = 0.01). Combining previously published urinary p75ECD results from 22 ALS patients with a further 24 ALS patients, baseline urinary p75ECD was also higher compared to healthy controls (6.0 ± 2.7 vs. 3.2 ± 1.0 ng/mg creatinine, p < 0.0001) and correlated with the Revised ALS Functional Rating Scale (r = −0.36, p = 0.01). Urinary neopterin and p75ECD correlated with each other at baseline (r = 0.38, p = 0.009). In longitudinal analysis, urinary neopterin increased on average (±SE) by 6.8 ± 1.1 µmol/mol creatinine per month (p < 0.0001) and p75ECD by 0.19 ± 0.02 ng/mg creatinine per month (p < 0.0001) from diagnosis in 29 ALS patients.Conclusion: Urinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti‐inflammatory therapies.
- Open Access
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (4) , 108323
Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (4) , 108323
Open AccessGenome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics
- Open Access
- 24 September 2020
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 22 (3-4) , 287-299
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow...
- 24 September 2020
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 22 (3-4) , 287-299
Open AccessA Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow...
- 1 December 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 407, 116540
Factors contributing to delays in the diagnosis of motor neuron disease – A South Australian study
- 1 December 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 407, 116540
Factors contributing to delays in the diagnosis of motor neuron disease – A South Australian study
- 31 October 2019
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (sup1) , 289-300
Theme 10 Disease stratification and phenotyping of patients
Background: MND is a progressive neurodegenerative disease characterised by death of upper and lower motor neurons, leading to progressive weakness of the bulbar, limb, thoracic and abdominal muscles. MND has a fairly stereotypical course, with death from respiratory failure occurring 2-4 years after symptom onset in most cases ( 1 ForsgrenL , AlmayBG , HolmgrenG , et al. Acta Neurol Scand. 1983;68:20–29. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Making the diagnosis of MND can be straightforward when key clinical criteria are met; however, at first presentation, rarely do patients meet these criteria, neurological changes may be subtle and disease progression slow. Thus, diagnosis poses a significant challenge, particularly in general practice, where patients are most likely to first present. Not surprisingly, there is usually a delay of 10-18 months between symptom onset and MND diagnosis ( 2 ChiòA , MoraG , CalvoA , et al. Neurology. 2009; 72(8):725–31. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Importantly, early assessment by a neurologist is associated with a shorter time to MND diagnosis ( 3 MitchellJD , CallagherP , GardhamJ , et al. Amyotroph Lateral Scler. 2010;11(6):537–41. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ), which has significant implications for access to healthcare, including Riluzole and multidisciplinary clinics, which improve survival ( 4 RooneyJ , ByrneS , HeverinM , et al. J Neurol Neurosurg Psychiatry. 2015;86(5):496–501. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Although delay in diagnosis is well documented, there have been no studies that have sought to identify factors associated with time to diagnosis, thereby enabling targeted implementation of a public health intervention. Objectives: To characterise the clinical factors that influence time to diagnosis of MND. Methods: 112 patients with MND attending the Southern Adelaide MND Clinic enrolled between January 2016 - 2018 were retrospectively recruited in to a cohort study. Information pertaining to the patient’s demographics and their journey to diagnosis collected by a specialist physician and stored in the Australian MND Registry during clinic review were analysed to identify factors associated with time to diagnosis. Results: Mean time to diagnosis was 13 ± 1 months (range 1 – 38 months) from symptom onset. 41% of patients were classified as having fast disease progression; compared to those with slow disease progression, these patients were diagnosed earlier (8 ± 1 months vs 16 ± 2 months) (p < 0.0001, t = 34.6, df =220), were less likely to undergo multiple specialist opinions prior to referral to a neurologist (53% vs 73%) (p < 0.05, Chi-squared = 9.5, df =1), and were more disabled at time of diagnosis (mean ALSFRS-R 33 ± 5 vs ALSFRS-R 41 ± 5) (p < 0.0001, t = 12.4, df =220). Discussion and conclusions: Fast disease progression identifies a dichotomy of MND patients diagnosed earlier, although more disabled at diagnosis, likely mediated by a more efficient referral process. A greater awareness of MND is required to shorten time to diagnosis.
- 31 October 2019
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (sup1) , 289-300
Theme 10 Disease stratification and phenotyping of patients
Background: MND is a progressive neurodegenerative disease characterised by death of upper and lower motor neurons, leading to progressive weakness of the bulbar, limb, thoracic and abdominal muscles. MND has a fairly stereotypical course, with death from respiratory failure occurring 2-4 years after symptom onset in most cases ( 1 ForsgrenL , AlmayBG , HolmgrenG , et al. Acta Neurol Scand. 1983;68:20–29. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Making the diagnosis of MND can be straightforward when key clinical criteria are met; however, at first presentation, rarely do patients meet these criteria, neurological changes may be subtle and disease progression slow. Thus, diagnosis poses a significant challenge, particularly in general practice, where patients are most likely to first present. Not surprisingly, there is usually a delay of 10-18 months between symptom onset and MND diagnosis ( 2 ChiòA , MoraG , CalvoA , et al. Neurology. 2009; 72(8):725–31. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Importantly, early assessment by a neurologist is associated with a shorter time to MND diagnosis ( 3 MitchellJD , CallagherP , GardhamJ , et al. Amyotroph Lateral Scler. 2010;11(6):537–41. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ), which has significant implications for access to healthcare, including Riluzole and multidisciplinary clinics, which improve survival ( 4 RooneyJ , ByrneS , HeverinM , et al. J Neurol Neurosurg Psychiatry. 2015;86(5):496–501. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Although delay in diagnosis is well documented, there have been no studies that have sought to identify factors associated with time to diagnosis, thereby enabling targeted implementation of a public health intervention. Objectives: To characterise the clinical factors that influence time to diagnosis of MND. Methods: 112 patients with MND attending the Southern Adelaide MND Clinic enrolled between January 2016 - 2018 were retrospectively recruited in to a cohort study. Information pertaining to the patient’s demographics and their journey to diagnosis collected by a specialist physician and stored in the Australian MND Registry during clinic review were analysed to identify factors associated with time to diagnosis. Results: Mean time to diagnosis was 13 ± 1 months (range 1 – 38 months) from symptom onset. 41% of patients were classified as having fast disease progression; compared to those with slow disease progression, these patients were diagnosed earlier (8 ± 1 months vs 16 ± 2 months) (p < 0.0001, t = 34.6, df =220), were less likely to undergo multiple specialist opinions prior to referral to a neurologist (53% vs 73%) (p < 0.05, Chi-squared = 9.5, df =1), and were more disabled at time of diagnosis (mean ALSFRS-R 33 ± 5 vs ALSFRS-R 41 ± 5) (p < 0.0001, t = 12.4, df =220). Discussion and conclusions: Fast disease progression identifies a dichotomy of MND patients diagnosed earlier, although more disabled at diagnosis, likely mediated by a more efficient referral process. A greater awareness of MND is required to shorten time to diagnosis.
- Top Cited Papers
- 1 July 2019
- Published by Elsevier in The Lancet
- Vol. 394 (10193) , 139-147
Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
- 1 July 2019
- Published by Elsevier in The Lancet
- Vol. 394 (10193) , 139-147
Top Cited PapersExtending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data